DORA

San Francisco Declaration on Research Assessment

DSC_0283_cleaned_small

From Sequence to Function

Kasuga Grand Shrine, Nara

Young British Researchers Visit Japan

Slide1

Journal club on the Node

Disease Models & Mechanisms (DMM) announces new Editor-in-Chief and Senior Editors

Posted by on April 25th, 2013

DMM_logo_100

 

This week, Disease Models & Mechanisms (DMM) formally announced the appointment of a new team of academic editors to lead the journal. Ross Cagan, Associate Dean of the Graduate School for Biological Sciences at Mount Sinai Medical Center, succeeds Vivian Siegel as the Editor-in-Chief, and he is joined by Senior Editors Monica Justice, Professor of Molecular and Human Genetics at Baylor College of Medicine, and George Tidmarsh, Chief Executive Officer at La Jolla Pharmaceutical Company.

Ross, Monica and George describe their interest in and vision for DMM in an inaugural editorial published in the latest issue of the journal. “This is a challenging but also an exciting time for science”, they write. “Our tools are not only more powerful, their level of improvement itself is accelerating. Not surprisingly, we are now trying to imagine how these tools can be applied to disease. What we find remarkable is that the founders of DMM understood these trends years ago.”

Describing some of the obstacles to the translation of biological findings to clinical benefit, they continue: “Many of the failures we have seen in translating novel basic biological discoveries to useful medicines are a result of the inadequacies of the animal models we use at the critical juncture between bench and bedside”. To address these inadequacies and promote future drug development, the team aims to introduce new standards for the rigorous preclinical assessment of animal models of disease.

Another issue raised is the lack of reproducibility of scientific findings, which has been reported in several journals. The new editors argue that negative data can be as informative as positive data when exploring therapeutics, so aim to encourage the publication of useful negative results: “….we will help promote –through our publications – a change in the scientific culture responsible for the asymmetric publication of positive results”.

Vivian Siegel, Broad Institute of MIT and Harvard, has stepped down after four years as Editor-in-Chief. In her farewell editorial, she reflects on the changes that DMM has undergone since launch, including the move to become open-access and, recently, a change in Creative Commons license to further promote access and sharing.

“About a year and a half ago, I agreed to become the Director of Scientific Education and Public Communications at the Broad Institute of MIT and Harvard, and realized I would have limited time to devote to DMM, too little to give it what it needs to continue to grow” Vivian writes, explaining her decision to leave DMM. “I encouraged The Company of Biologists to identify academic editors instead of another professional editor to succeed me, as I felt that the journal had now reached an age where its lead editors should be researchers actively engaged in the work covered by the journal.”

DMM is an open-access biomedical journal that publishes research and reviews focusing on the use of model organisms to provide insight into disease mechanisms, diagnostics and therapeutics. Founded in 2008, the journal was the fourth to be launched by the Company of Biologists.

To find out more and access the latest issue of the journal, go to http://dmm.biologists.org/
GD Star Rating
loading…
Share

Tags , , ,
Category News | No Comments »

The IMPC: a new era in mouse genetics

Posted by on April 26th, 2012

The sophistication of genetic tools and the relative ease of breeding and housing mean that the mouse is the most widely used mammalian organism for basic and biomedical research. The genotype-phenotype information that will emerge from the efforts of the International Mouse Phenotyping Consortium (IMPC), now well into its first year, will advance all areas of the biological sciences, from behaviour to drug discovery, oncology to developmental biology.

The IMPC is one of the largest model-organism-based initiatives ever funded. Its aim is to generate and comprehensively characterise the phenotypes of viable knockouts for every gene in the mouse genome, and to compile the information in a public database (Brown & Moore, 2012). In practical terms, this means creating ~20,000 viable mouse lines and phenotyping them using dozens of tests, a feat that will be carried out through the coordinated efforts of several institutes in nine different countries. Moreover, the ~30% of knockouts that are expected to show embryonic lethality will be characterised, where possible, using specialised tests performed during embryonic development. The number and sophistication of tests used for phenotyping will likely increase as the protocols are refined and improved, and as notable mouse strains are selected for specialised phenotyping in secondary screens. For example, histopathology – the analysis of disease correlates through microscopic examination of tissues obtained from necropsy or biopsy – provides invaluable information that is complementary to in vivo assays, but it can currently only be performed on selected lines owing to economical and logistical constraints (Schofield et al., 2012).

The resources that will be generated by the IMPC include free access to all knockout mouse lines (or sperm) and a comprehensive database of corresponding phenotype information. These resources generated will be of value to investigators at all levels, and in many disciplines, from undergraduates to group leaders, basic scientists to clinicians.

Further reading

Brown, S. D. M. and Moore, M. Towards an encyclopaedia of mammalian gene function: the International Mouse Phenotyping Consortium. (2012). Dis. Model. Mech. 5, 289-292.

Schofield P. N., Vogel, P., Gkoutos G. V., Sundberg, J. P. (2012). Exploring the elephant: histopathology in high-throughput phenotyping of mutant mice. Dis. Model. Mech. 5, 19-25.

Straight talk with… Steve Brown. Interview by Hannah Waters. (2011). Nat. Med. 17, 1332.

January 2012 DMM Podcast: Paul Schofield on histopathology in high-throughput phenotyping of mutant mice.

IMPC website: http://www.mousephenotype.org/

 

 
GD Star Rating
loading…
Share

Tags , , , , , ,
Category Research, Resources | No Comments »

Recombine to get better

Posted by on September 6th, 2010

ResearchBlogging.org Recently a paper in Science caught my attention since its title combines the words mitotic recombination with patients and Ichthyosis. Having worked with Drosophila during my PhD and now being in a vertebrate lab, I’m well aware of the existence of tools to induce mitotic recombination to generate somatic clones of mutant cells in certain tissues. So I had a closer look at the paper to understand more about the spontaneous occurrence of mitotic recombination in humans.

“Ichthyosis with confetti” (that’s what it’s called!), or IWC for short, is a very rare sporadic skin disease. Patients display red skin because their skin barrier is defective and they often die of bacterial infections. The reason the disease carries the word confetti in its name is that in the first year of life, the otherwise reddish body starts to be covered in pale spots, resembling confetti, which increase in number and size with age.

Now it has been found that these pale spots are clones of “revertant” cells arising through mitotic recombination. Most cells in the body of IWC patients are heterozygous for a spontaneous dominant mutation in the keratin 10 (KRT10) gene that causes the red skin disease phenotype. The exact mutation in KRT10 differs between patients, but all of the mutations result in frameshifts in the same alternative reading frame of KRT10. The product of this is an arginine-rich peptide that mis-localizes to the nucleolus and thereby disrupts the keratin filament network of skin cells. The pale clones of revertant cells are formed when mitotic recombination causes loss of heterozygosity in KRT10, so that these clones no longer carry the mutation and therefore behave like normal cells. Reversion to wild type occurs at very high frequency, suggesting a general increase in the rate of mitotic recombination in these individuals. It is not yet known what causes this elevation.

So, what did I learn from this? Mitotic recombination in multicellular organisms is not just a peculiarity that can be useful for experiments in model systems, it also occurs naturally in humans. For reasons still unknown, its rate can be increased when beneficial for the cells affected. Cancer cells appear to exploit this phenomenon, increasing the rate of mitotic recombination to speed loss of heterozygosity of tumor suppressor mutations to promote their survival and growth.

Who knows, one day induction of mitotic recombination to remove undesired mutations might even be used as a therapy in humans, as long as the homozygous mutant sister cells eliminate themselves as seems to be the case in IWC. As always, the frightening part in this scenario is the possibility of losing control and causing unwanted and potentially harmful mutations. We’ll see.



Choate KA, Lu Y, Zhou J, Choi M, Elias PM, Farhi A, Nelson-Williams C, Crumrine D, Williams ML, Nopper AJ, Bree A, Milstone LM, & Lifton RP (2010). Mitotic Recombination in Patients with Ichthyosis Causes Reversion of Dominant Mutations in KRT10. Science (New York, N.Y.) PMID: 20798280
GD Star Rating
loading…
Share

Tags , , , ,
Category Research | 2 Comments »

Phenologs and unlikely models

Posted by on September 1st, 2010

ResearchBlogging.org“You’re probably wondering why I’m here”, were the first words of Edward Marcotte’s talk at the SDB meeting last month. After all, he was about to speak about systems biology in a session on organogenesis. What followed was not only a new way to identify genes involved in developmental processes, but also a perfect example of the kind of unexpected discoveries that can be made using publicly available data.

Edward Marcotte is a bioinformatician at the University of Texas at Austin. His lab introduced the concept of phenologs to discover non-obvious disease models and candidate genes, and at the SDB meeting, as well as in a recent paper, he described exactly how “non-obvious” some of those models are: If a yeast model for angiogenesis doesn’t sound unlikely enough, the group also proposed a plant model for Waardenburg syndrome!

The concept behind phenologs is that a set of genes related to a phenotype in one organism may correspond to an orthologous set of genes in another organism. Orthologues are homologous genes between different species, but this does not necessarily mean that the same gene is linked to the same phenotype in both organisms. Marcotte looked at groups of orthologues: If a group of genes is linked to a certain phenotype in one organism, and that same group results in another phenotype in a second organism, then those two phenotypes are phenologs.


The concept of phenologs. (Figure 1B in the PNAS paper.)



In one practical example from the paper, known gene-phenotype associations from yeast were compared with known gene-phenotype associations from mice, using information from publicly available yeast and mouse genome databases. This showed that many genes that are associated with abnormal angiogenesis in mice have orthologous genes in yeast. Of course yeast doesn’t have a circulation system, so these genes can’t possibly be associated with angiogenesis in yeast, and indeed they’re not: In yeast, these same genes are involved in sensitivity to the hypercholesterolemia drug lovastatin. This suggests that lovastatin sensitivity in yeast could be a model for angiogenesis in vertebrates. To prove this, follow-up experiments showed that the transcription factor SOX13, which was identified as lovastatin-sensitive in yeast, is required for vascular development in Xenopus.

Even more surprising than finding angiogenesis genes in yeast, is that a similar comparison of phenologs suggests a plant model for Waardenburg syndrome. This disorder is caused by impaired neural crest development, and is marked by pigmentation defects and craniofacial malformations. Phenologs showed that many genes associated with Arabidopsis failing to grow in response to gravity (gravitropism) were orthologous to human genes mutated in Waardenburg syndrome, which suggests that other gravitropism genes may serve as starting points to look for other factors involved in neural crest migration.

While I was listening to this talk, I wondered whether the people who did the original yeast lovastatin screens could ever have imagined their data being used to find a new factor involved in angiogenesis. And the groups that identified gravitropism-related genes in Arabidopsis must never have thought that this could even remotely have anything to do with Waardenburg syndrome in humans! It illustrates exactly why it’s important to make data from screens and large-scale studies available to others: You often only use a small amount of the data, and buried among the rest of it is information that could be useful to people you’d never expect would benefit from it! The data in public databases speeds up research and opens up new subjects of investigation, and that is exactly why it’s there.

Read the rest of this entry »
GD Star Rating
loading…
Share

Tags , , , ,
Category Research | 3 Comments »


Copyright 2010 - 2012 The Company of Biologists Ltd

Company of Biologists